ASCO 2025 | DREAMseq: 5-year follow up of first-line dual IO in BRAFV600-m melanoma
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, reviews the latest results from the Phase III DREAMseq trial (NCT02224781), which evaluated first-line treatment with nivolumab plus ipilimumab versus dabrafenib plus trametinib in patients with previously untreated BRAFV600-mutant metastatic melanoma. After nearly five years of follow-up, dual immunotherapy (IO) continued to show a lasting overall survival benefit. While response rates were comparable between groups, the durability of response and progression-free survival were superior with the nivolumab and ipilimumab regimen. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
